These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
414 related articles for article (PubMed ID: 10756367)
1. Incidence and characterization of secondary myelodysplastic syndromes following autologous transplantation. Del Cañizo Mf; Amigo Mf; Hernández JM; Sanz G; Núñez R; Carreras E; Alegre A; Cuesta B; Mataix R Haematologica; 2000 Apr; 85(4):403-9. PubMed ID: 10756367 [TBL] [Abstract][Full Text] [Related]
2. Secondary myelodysplastic syndrome and acute myelogenous leukemia are significant complications following autologous stem cell transplantation for lymphoma. Howe R; Micallef IN; Inwards DJ; Ansell SM; Dewald GW; Dispenzieri A; Gastineau DA; Gertz MA; Geyer SM; Hanson CA; Lacy MQ; Tefferi A; Litzow MR Bone Marrow Transplant; 2003 Aug; 32(3):317-24. PubMed ID: 12858205 [TBL] [Abstract][Full Text] [Related]
3. Periodic morphologic, cytogenetic and clonality evaluation after autologous peripheral blood progenitor cell transplantation in patients with lymphoproliferative malignancies. Laurenti L; Chiusolo P; Garzia MG; Zini G; Sorà F; Piccirillo N; Piccioni P; Zollino M; Leone G; Sica S Haematologica; 2002 Jan; 87(1):59-66. PubMed ID: 11801466 [TBL] [Abstract][Full Text] [Related]
4. Secondary acute myeloid leukemia and myelodysplasia after autologous peripheral blood progenitor cell transplantation. Sevilla J; Rodríguez A; Hernández-Maraver D; de Bustos G; Aguado J; Ojeda E; Arrieta R; Hernández-Navarro F Ann Hematol; 2002 Jan; 81(1):11-5. PubMed ID: 11807629 [TBL] [Abstract][Full Text] [Related]
5. Myelodysplasia and acute leukemia following high-dose chemotherapy and autologous bone marrow or peripheral blood stem cell transplantation. Sobecks RM; Le Beau MM; Anastasi J; Williams SF Bone Marrow Transplant; 1999 Jun; 23(11):1161-5. PubMed ID: 10382956 [TBL] [Abstract][Full Text] [Related]
6. Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study Group. Josting A; Wiedenmann S; Franklin J; May M; Sieber M; Wolf J; Engert A; Diehl V; J Clin Oncol; 2003 Sep; 21(18):3440-6. PubMed ID: 12668650 [TBL] [Abstract][Full Text] [Related]
7. Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: a 16-year follow-up study. Sacchi S; Marcheselli L; Bari A; Marcheselli R; Pozzi S; Luminari S; Lombardo M; Buda G; Lazzaro A; Gobbi PG; Stelitano C; Morabito F; Quarta G; Brugiatelli M Haematologica; 2008 Mar; 93(3):398-404. PubMed ID: 18268277 [TBL] [Abstract][Full Text] [Related]
8. Autologous stem cell transplantation for therapy-related acute myeloid leukemia and myelodysplastic syndrome. Kröger N; Brand R; van Biezen A; Cahn JY; Slavin S; Blaise D; Sierra J; Zander A; Niederwieser D; de Witte T; Bone Marrow Transplant; 2006 Jan; 37(2):183-9. PubMed ID: 16299545 [TBL] [Abstract][Full Text] [Related]
9. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia. Kröger N; Bornhäuser M; Ehninger G; Schwerdtfeger R; Biersack H; Sayer HG; Wandt H; Schäfer-Eckardt K; Beyer J; Kiehl M; Zander AR; Ann Hematol; 2003 Jun; 82(6):336-42. PubMed ID: 12728337 [TBL] [Abstract][Full Text] [Related]
10. High-dose therapy and autologous hematopoietic stem-cell transplantation does not increase the risk of second neoplasms for patients with Hodgkin's lymphoma: a comparison of conventional therapy alone versus conventional therapy followed by autologous hematopoietic stem-cell transplantation. Forrest DL; Hogge DE; Nevill TJ; Nantel SH; Barnett MJ; Shepherd JD; Sutherland HJ; Toze CL; Smith CA; Lavoie JC; Song KW; Voss NJ; Gascoyne RD; Connors JM J Clin Oncol; 2005 Nov; 23(31):7994-8002. PubMed ID: 16204014 [TBL] [Abstract][Full Text] [Related]
11. Low incidence of secondary neoplasia after autotransplantation for lymphoproliferative disease: the role of pre-transplant therapy. Laurenti L; Tarnani M; Chiusolo P; La Torre G; Garzia M; Zollino M; Zini G; Balducci M; Leone G; Sica S Clin Transplant; 2008; 22(2):191-9. PubMed ID: 18339139 [TBL] [Abstract][Full Text] [Related]
12. Secondary acute leukemia following mitoxantrone-based high-dose chemotherapy for primary breast cancer patients. Kröger N; Damon L; Zander AR; Wandt H; Derigs G; Ferrante P; Demirer T; Rosti G; ; ; Bone Marrow Transplant; 2003 Dec; 32(12):1153-7. PubMed ID: 14647269 [TBL] [Abstract][Full Text] [Related]
13. Myelodysplasias and leukemias after autologous stem cell transplantation for lymphoid malignancies. Park S; Brice P; Noguerra ME; Simon D; Rousselot P; Kerneis Y; Morel P; Marolleau JP; Gisselbrecht C Bone Marrow Transplant; 2000 Aug; 26(3):321-6. PubMed ID: 10967573 [TBL] [Abstract][Full Text] [Related]
14. Therapy-related myelodysplasia and secondary acute myelogenous leukemia after high-dose therapy with autologous hematopoietic progenitor-cell support for lymphoid malignancies. Micallef IN; Lillington DM; Apostolidis J; Amess JA; Neat M; Matthews J; Clark T; Foran JM; Salam A; Lister TA; Rohatiner AZ J Clin Oncol; 2000 Mar; 18(5):947-55. PubMed ID: 10694543 [TBL] [Abstract][Full Text] [Related]
15. Risk factors before autologous stem-cell transplantation for lymphoma predict for secondary myelodysplasia and acute myelogenous leukemia. Kalaycio M; Rybicki L; Pohlman B; Sobecks R; Andresen S; Kuczkowski E; Bolwell B J Clin Oncol; 2006 Aug; 24(22):3604-10. PubMed ID: 16877727 [TBL] [Abstract][Full Text] [Related]
16. Factors influencing hematopoietic recovery after autologous blood stem cell transplantation in patients with acute myeloblastic leukemia and with non-myeloid malignancies. Carral A; de la Rubia J; Martín G; Martínez J; Sanz G; Jarque I; Sempere A; Soler MA; Marty ML; Sanz MA Bone Marrow Transplant; 2002 May; 29(10):825-32. PubMed ID: 12058232 [TBL] [Abstract][Full Text] [Related]
17. Chromosomal abnormalities in women with breast cancer after autologous stem cell transplantation are infrequent and may not predict development of therapy-related leukemia or myelodysplastic syndrome. Martínez-Climent JA; Comes AM; Vizcarra E; Benet I; Arbona C; Prósper F; Solano C; García Clavel B; Marugán I; Lluch A; García-Conde J Bone Marrow Transplant; 2000 Jun; 25(11):1203-8. PubMed ID: 10849534 [TBL] [Abstract][Full Text] [Related]
18. Long-term remissions in patients with myelodysplastic syndrome and secondary acute myelogenous leukemia undergoing allogeneic transplantation following a reduced intensity conditioning regimen of 550 cGy total body irradiation and cyclophosphamide. Hallemeier CL; Girgis MD; Blum WG; Brown RA; Khoury HJ; Devine SM; Vij R; Lin HS; DiPersio JF; Adkins DR Biol Blood Marrow Transplant; 2006 Jul; 12(7):749-57. PubMed ID: 16785064 [TBL] [Abstract][Full Text] [Related]